|
1
|
Kansagara D, Papak J, Pasha AS, O'Neil M,
Freeman M, Relevo R, Quiñones A, Motu'apuaka M and Jou JH:
Screening for hepatocellular carcinoma in chronic liver disease: A
systematic review. Ann Intern Med. 161:261–269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanyal AJ, Yoon SK and Lencioni R: The
etiology of hepatocellular carcinoma and consequences for
treatment. Oncologist. 15:(Suppl 4). 14–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tejeda-Maldonado J, García-Juárez I,
Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M,
Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF and
Carrillo-Pérez DL: Diagnosis and treatment of hepatocellular
carcinoma: An update. World J Hepatol. 7:362–376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cai QQ, Dong YW, Wang R, Qi B, Guo JX, Pan
J, Liu YY, Zhang CY and Wu XZ: MiR-124 inhibits the migration and
invasion of human hepatocellular carcinoma cells by suppressing
integrin αV expression. Sci Rep. 7:407332017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuo MT: Redox regulation of multidrug
resistance in cancer chemotherapy: Molecular mechanisms and
therapeutic opportunities. Antioxid Redox Signal. 11:99–133. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blum HE: Hepatocellular carcinoma: Therapy
and prevention. World J Gastroenterol. 11:7391–7400.
2005.PubMed/NCBI
|
|
7
|
Miska EA: How microRNAs control cell
division, differentiation and death. Curr Opin Genet Dev.
15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mendell JT: MicroRNAs: Critical regulators
of development, cellular physiology and malignancy. Cell Cycle.
4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhan MN, Yu XT, Tang J, Zhou CX, Wang CL,
Yin QQ, Gong XF, He M, He JR, Chen GQ, et al: MicroRNA-494 inhibits
breast cancer progression by directly targeting PAK1. Cell Death
Dis. 8:e25292017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu G, Jia Z and Dou Z: miR-24-3p regulates
bladder cancer cell proliferation, migration, invasion and
autophagy by targeting DEDD. Oncol Rep. 37:1123–1131.
2017.PubMed/NCBI
|
|
15
|
Lee SW, Park KC, Kim JG, Moon SJ, Kang SB,
Lee DS, Sul HJ, Ji JS and Jeong HY: Dysregulation of
MicroRNA-196b-5p and MicroRNA-375 in Gastric Cancer. J Gastric
Cancer. 16:221–229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dai L, Wang Y, Chen L, Zheng J, Li J and
Wu X: MiR-221, a potential prognostic biomarker for recurrence in
papillary thyroid cancer. World J Surg Oncol. 15:112017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu M, Xue H, Wang Y, Shen Q, Jiang Q,
Zhang X, Li K, Jia M, Jia J, Xu J, et al: miR-345 inhibits tumor
metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT
pathway in hepatocellular carcinoma. Int J Oncol. 50:975–983.
2017.PubMed/NCBI
|
|
18
|
Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou
J: MicroRNA-133 inhibits cell proliferation, migration and invasion
by targeting epidermal growth factor receptor and its downstream
effector proteins in bladder cancer. Scand J Urol. 47:423–432.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun C, Huang C, Li S, Yang C, Xi Y, Wang
L, Zhang F, Fu Y and Li D: Hsa-miR-326 targets CCND1 and inhibits
non-small cell lung cancer development. Oncotarget. 7:8341–8359.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu L, Hui H, Wang LJ, Wang H, Liu QF and
Han SX: MicroRNA-326 functions as a tumor suppressor in colorectal
cancer by targeting the nin one binding protein. Oncol Rep.
33:2309–2318. 2015.PubMed/NCBI
|
|
22
|
Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F
and Pei HH: miR-186 and 326 predict the prognosis of pancreatic
ductal adenocarcinoma and affect the proliferation and migration of
cancer cells. PLoS One. 10:e01188142015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang
K, Wagar N, Yoon Y, Cho HT, Scala S, et al: Involvement of miR-326
in chemotherapy resistance of breast cancer through modulating
expression of multidrug resistance-associated protein 1. Biochem
Pharmacol. 79:817–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang B, Feng P, Xiao Z and Ren EC: LIM and
SH3 protein 1 (Lasp1) is a novel p53 transcriptional target
involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang H, Li W, Jin X, Cui S and Zhao L: LIM
and SH3 protein 1, a promoter of cell proliferation and migration,
is a novel independent prognostic indicator in hepatocellular
carcinoma. Eur J Cancer. 49:974–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang J, Zhou ZG, Huang ZX, Yang KL, Chen
JC, Chen JB, Xu L, Chen MS and Zhang YJ: Prospective, single-center
cohort study analyzing the efficacy of complete laparoscopic
resection on recurrent hepatocellular carcinoma. Chin J Cancer.
35:252016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J, Han S, Huang W, Chen T, Liu Y, Pan
S and Li S: A meta-analysis of microRNA expression in liver cancer.
PLoS One. 9:e1145332014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao B and Wang G: MicroRNAs involved with
hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820.
2015.PubMed/NCBI
|
|
32
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J, Xu T, Yan Y, Qin R, Wang H, Zhang
X, Huang Y, Wang Y, Lu Y, Fu D, et al: MicroRNA-326 functions as a
tumor suppressor in glioma by targeting the Nin one binding protein
(NOB1). PLoS One. 8:e684692013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kefas B, Comeau L, Erdle N, Montgomery E,
Amos S and Purow B: Pyruvate kinase M2 is a target of the
tumor-suppressive microRNA-326 and regulates the survival of glioma
cells. Neuro-Oncol. 12:1102–1112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang S, Lu S, Geng S, Ma S, Liang Z and
Jiao B: Expression and clinical significance of microRNA-326 in
human glioma miR-326 expression in glioma. Med Oncol. 30:3732013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Gao Y, Xu Y, Ma H and Yang M:
Down-regulation of miR-326 is associated with poor prognosis and
promotes growth and metastasis by targeting FSCN1 in gastric
cancer. Growth Factors. 33:267–274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ji S, Zhang B, Kong Y, Ma F and Hua Y:
MiR-326 inhibits gastric cancer cell growth through down regulating
NOB1. Oncol Res. Oct 11–2016.(Epub ahead of print).
|
|
38
|
Cao L, Wang J and Wang PQ: MiR-326 is a
diagnostic biomarker and regulates cell survival and apoptosis by
targeting Bcl-2 in osteosarcoma. Biomed Pharmacother. 84:828–835.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yin S, Du W, Wang F, Han B, Cui Y, Yang D,
Chen H, Liu D, Liu X and Jiang C: MicroRNA-326 sensitizes human
glioblastoma cells to curcumin via the SHH/GLI1 signaling pathway.
Cancer Biol Ther. Nov 7–2016.(Epub ahead of print). View Article : Google Scholar :
|
|
40
|
Du W, Liu X, Chen L, Dou Z, Lei X, Chang
L, Cai J, Cui Y, Yang D, Sun Y, et al: Targeting the SMO oncogene
by miR-326 inhibits glioma biological behaviors and stemness.
Neuro-Oncol. 17:243–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li D, Du X, Liu A and Li P: Suppression of
nucleosome-binding protein 1 by miR-326 impedes cell proliferation
and invasion in non-small cell lung cancer cells. Oncol Rep.
35:1117–1124. 2016.PubMed/NCBI
|
|
42
|
Wang R, Chen X, Xu T, Xia R, Han L, Chen
W, De W and Shu Y: MiR-326 regulates cell proliferation and
migration in lung cancer by targeting phox2a and is regulated by
HOTAIR. Am J Cancer Res. 6:173–186. 2016.PubMed/NCBI
|
|
43
|
Li J, Li S, Chen Z, Wang J, Chen Y, Xu Z,
Jin M and Yu W: miR-326 reverses chemoresistance in human lung
adenocarcinoma cells by targeting specificity protein 1. Tumour
Biol. 37:13287–13294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai M, Wang Z, Zhang J, Zhou H, Jin L, Bai
R and Weng Y: Adam17, a Target of Mir-326, Promotes Emt-Induced
Cells Invasion in Lung Adenocarcinoma. Cell Physiol Biochem.
36:1175–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tomasetto C, Moog-Lutz C, Régnier CH,
Schreiber V, Basset P and Rio MC: Lasp-1 (MLN 50) defines a new LIM
protein subfamily characterized by the association of LIM and SH3
domains. FEBS Lett. 373:245–249. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Grunewald TG and Butt E: The LIM and SH3
domain protein family: Structural proteins or signal transducers or
both? Mol Cancer. 7:312008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang C, Zheng X, Shen C and Shi Y:
MicroRNA-203 suppresses cell proliferation and migration by
targeting BIRC5 and LASP1 in human triple-negative breast cancer
cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma
M and Liu JF: The tumor-suppressive function of miR-1 by targeting
LASP1 and TAGLN2 in esophageal squamous cell carcinoma. J
Gastroenterol Hepatol. 31:384–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang H, Shi J, Luo Y, Liao Q, Niu Y, Zhang
F, Shao Z, Ding Y and Zhao L: LIM and SH3 protein 1 induces
TGFβ-mediated epithelial-mesenchymal transition in human colorectal
cancer by regulating S100A4 expression. Clin Cancer Res.
20:5835–5847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhao T, Ren H, Li J, Chen J, Zhang H, Xin
W, Sun Y, Sun L, Yang Y, Sun J, et al: LASP1 is a HIF1α target gene
critical for metastasis of pancreatic cancer. Cancer Res.
75:111–119. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hailer A, Grunewald TG, Orth M, Reiss C,
Kneitz B, Spahn M and Butt E: Loss of tumor suppressor mir-203
mediates overexpression of LIM and SH3 Protein 1 (LASP1) in
high-risk prostate cancer thereby increasing cell proliferation and
migration. Oncotarget. 5:4144–4153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chiyomaru T, Enokida H, Kawakami K,
Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa
M: Functional role of LASP1 in cell viability and its regulation by
microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Grunewald TG, Kammerer U, Schulze E,
Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1
influences zyxin localization, inhibits proliferation and reduces
migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang
S, Sun X, Li J, Deng Y, Jiang Y, et al: Promotion of colorectal
cancer growth and metastasis by the LIM and SH3 domain protein 1.
Gut. 59:1226–1235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Salvi A, Bongarzone I, Ferrari L, Abeni E,
Arici B, De Bortoli M, Scuri S, Bonini D, Grossi I, Benetti A, et
al: Molecular characterization of LASP-1 expression reveals
vimentin as its new partner in human hepatocellular carcinoma
cells. Int J Oncol. 46:1901–1912. 2015.PubMed/NCBI
|
